JAK inhibitors and black box warnings: what is the future for JAK inhibitors?-Reference-Cited by-同舟云学术

JAK inhibitors and black box warnings: what is the future for JAK inhibitors?

Published:2023-09-04 Issue:11 Volume:19 Page:1385-1397
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Tokareva Kate¹,Reid Pankti²^ORCID,Yang Victor³^ORCID,Liew David³⁴^ORCID,Peterson Alexander C.⁵,Baraff Aaron⁵,Giles Jon⁶,Singh Namrata⁷^ORCID

Affiliation:

1. Medical Student, University of Washington, Seattle, WA, USA

2. Division of Rheumatology and Committee on Clinical Pharmacology and Pharmacogenomics, Department of Medicine, University of Chicago Biological Sciences Division, Chicago, IL, USA

3. Department of Rheumatology, Austin Health, Melbourne, Victoria, Australia

4. Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Victoria, Australia

5. Seattle Epidemiologic Research and Information Center (ERIC), VA Puget Sound Healthcare System, Seattle, WA, USA

6. Columbia University, New York, NY, USA

7. Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA

Funder

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institutes of Health

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2023.2249237

Reference110 articles.

1. Current and future status of JAK inhibitors

2. A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?

3. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis;Hodge JA;Clin Exp Rheumatol,2016

4. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

5. A Comprehensive Overview of Globally Approved JAK Inhibitors

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16

2. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review;Dermatology and Therapy;2024-05-19

3. Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine;Saudi Journal of Gastroenterology;2024-04-10

4. Revolutionizing the management of patients with atopic dermatitis: practical considerations;Expert Opinion on Biological Therapy;2024-03-24

5. Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology;Current Opinion in Rheumatology;2023-12-20